Carcinoembryonic antigen as a marker in patients with breast cancer receiving postsurgical adjuvant chemotherapy

✍ Scribed by Hèndré C. Falkson; Geoffrey Falkson; M. Antonia Portugal; Johnnie J. Van Der Watt; Hermanus S. Schoeman

• Publisher: John Wiley and Sons
• Year: 1982
• Tongue: English
• Weight: 535 KB
• Volume: 49
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19820501)49:9<1859::aid-cncr2820490919>3.0.co;2-r

✦ Synopsis

Serial plasma CEA levels were determined over a period of 1-3 years in 114 patients receiving adjuvant chemotherapy for T1, 2 or 3a N+ MO breast cancer. CEA values were correlated with clinical status, scintiscans, and other biochemical parameters. CEA values >2.5 ng/ml were considered abnormal. Forty-one patients had normal values throughout the adjuvant period. In 73 patients where abnormal values occurred, four different patterns were seen: (1) a statistically significant number (30/73) had initial elevations with a decreasing titer; (2) rising titer (10/73); (3) fluctuating titer of transient elevation (25/73); and (4) persistent elevation (8/73). Seventeen patients developed overt metastases, this was associated with a rising CEA in nine patients (P < 0.002). CEA was more sensitive for predicting relapse than alkaline phosphatase or LDH. The correlation between CEA determination and the eventual development of metastatic disease is striking, and has implications for the design of future clinical trials. Results indicate that CEA could be used to identify high risk patients, to estimate efficacy of chemotherapeutic regime, and to determine optimal duration of therapy. Cancer 491859-1865, 1982.

DJUVANT THERAPY HAS MADE a remarkable im-A pact on the treatment of primary breast cancer.